Immunotherapies have been developed using specific antibodies, PD-1-PD-L1 checkpoint inhibitors, and improved antitumor immune responses to block PD-1-PD-L1 interactions and restore immune cell surveillance of tumor cells 11. This evidence concerns the gene CD274 and neoplasm.